CR10654A - Agentes que comprenden compuestos marcados con 18f y metodos relacionados - Google Patents

Agentes que comprenden compuestos marcados con 18f y metodos relacionados

Info

Publication number
CR10654A
CR10654A CR10654A CR10654A CR10654A CR 10654 A CR10654 A CR 10654A CR 10654 A CR10654 A CR 10654A CR 10654 A CR10654 A CR 10654A CR 10654 A CR10654 A CR 10654A
Authority
CR
Costa Rica
Prior art keywords
agents
related methods
compounds
compounds marked
understanding
Prior art date
Application number
CR10654A
Other languages
English (en)
Spanish (es)
Inventor
Lutz Lehamann
Ananth Srinivasan
Thomas Brumby
Detlev Sulzle
Timo Stellfeld
Keith Graham
Mylene Karramkam
Simon Ametamey
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06090166A external-priority patent/EP1897885A1/en
Priority claimed from EP07090079A external-priority patent/EP1985624A3/en
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CR10654A publication Critical patent/CR10654A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyridine Compounds (AREA)
CR10654A 2006-09-08 2009-03-05 Agentes que comprenden compuestos marcados con 18f y metodos relacionados CR10654A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06090166A EP1897885A1 (en) 2006-09-08 2006-09-08 Compounds and methods for F labelled agents
EP07090079A EP1985624A3 (en) 2007-04-23 2007-04-23 Single step method of radiofluorination of biologically active compounds or biomolecules

Publications (1)

Publication Number Publication Date
CR10654A true CR10654A (es) 2009-04-14

Family

ID=39031005

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10654A CR10654A (es) 2006-09-08 2009-03-05 Agentes que comprenden compuestos marcados con 18f y metodos relacionados

Country Status (20)

Country Link
US (1) US8557776B2 (cg-RX-API-DMAC7.html)
EP (5) EP3056509A1 (cg-RX-API-DMAC7.html)
JP (2) JP5603074B2 (cg-RX-API-DMAC7.html)
KR (1) KR20090058553A (cg-RX-API-DMAC7.html)
AR (1) AR062726A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007294124A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0716554A2 (cg-RX-API-DMAC7.html)
CA (2) CA2662449A1 (cg-RX-API-DMAC7.html)
CL (1) CL2007002620A1 (cg-RX-API-DMAC7.html)
CO (1) CO6150196A2 (cg-RX-API-DMAC7.html)
CR (1) CR10654A (cg-RX-API-DMAC7.html)
IL (4) IL197363A0 (cg-RX-API-DMAC7.html)
MA (1) MA30780B1 (cg-RX-API-DMAC7.html)
MX (1) MX2009002492A (cg-RX-API-DMAC7.html)
NO (1) NO20091428L (cg-RX-API-DMAC7.html)
PE (1) PE20080850A1 (cg-RX-API-DMAC7.html)
RU (1) RU2009112716A (cg-RX-API-DMAC7.html)
TN (1) TN2009000063A1 (cg-RX-API-DMAC7.html)
TW (1) TW200829277A (cg-RX-API-DMAC7.html)
WO (1) WO2008028688A2 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3056509A1 (en) 2006-09-08 2016-08-17 Piramal Imaging SA Bombesin analogues for use in diagnosis
MX2009009291A (es) * 2007-03-01 2009-12-14 Bayer Schering Pharma Ag Compuestos activos biologicamente marcados con fluoro-benzoilo 18f como agentes de diagnostico por imagenes asi como precursores de benzotriazol-1-iloxi-benzoilo, 2,5-dioxo-pirrolidin-1-iloxi benzoilo y trimetilamonio benzoilo.
GB201013808D0 (en) 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
WO2012094334A1 (en) * 2011-01-04 2012-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services One-step 18f labeling of biological substrates and uses of 18f labeled biological substrates
AU2012267998A1 (en) * 2011-06-09 2014-01-09 Ge Healthcare Limited Distillation device and method
AU2014228233B2 (en) * 2013-03-15 2019-02-28 Cancer Targeted Technology Llc 18F-labeled PSMA-targeted pet imaging agents
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
WO2018152339A1 (en) * 2017-02-17 2018-08-23 Yale University Radiolabeled pharmaceuticals and methods of making and using same
TW202426655A (zh) 2017-07-11 2024-07-01 美商新索思股份有限公司 非天然核苷酸之導入及其方法
US11622993B2 (en) 2017-08-03 2023-04-11 Synthorx, Inc. Cytokine conjugates for the treatment of autoimmune diseases
AU2019256714A1 (en) * 2018-04-20 2020-11-12 The General Hospital Corporation Acetylated prodrugs for delivery across the blood-brain barrier
KR20210123299A (ko) 2019-02-06 2021-10-13 신톡스, 인크. Il-2 콘쥬게이트 및 이의 사용 방법
CN113150065B (zh) * 2021-03-11 2022-07-08 武汉英纳氏药业有限公司 一种合成肽及其应用
US20240277876A1 (en) * 2021-05-20 2024-08-22 The Regents Of The University Of California Pet imaging tracers
KR20250164815A (ko) 2023-03-31 2025-11-25 닛산 가가쿠 가부시키가이샤 피라졸 화합물 및 유해 생물 방제제

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989002897A1 (en) 1987-09-24 1989-04-06 The Administrators Of The Tulane Educational Fund Therapeutic peptides
US5084555A (en) * 1989-08-21 1992-01-28 The Administrators Of The Tulane Educational Fund An octapeptide bombesin analog
US5723578A (en) * 1987-09-24 1998-03-03 The Administrators Of Tulane Educational Fund Peptide analogs of bombesin
HU208439B (en) * 1988-10-14 1993-10-28 Univ Tulane Process for producing pharmaceutical peptides
DE69023500D1 (de) * 1989-06-02 1995-12-14 Univ Georgetown Verfahren zum nachweis von antikörpern gegen streptokinase.
US6232071B1 (en) 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US5244883A (en) 1990-11-29 1993-09-14 The Administrators Of The Tulane Educational Fund Nonapeptide bombesin antagonists
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
AU2092599A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
WO1999033795A1 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
WO1999033792A2 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
US6639076B1 (en) * 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
WO2000076971A2 (en) 1999-06-14 2000-12-21 Eli Lilly And Company Serine protease inhibitors
AU2002228725A1 (en) * 2000-11-30 2002-06-11 Advanced Research And Technology Institute, Inc. Nucleophilic approach for preparing radiolabeled imaging agents and associated compounds
GB0115927D0 (en) 2001-06-29 2001-08-22 Nycomed Amersham Plc Solid-phase nucleophilic fluorination
GB0206750D0 (en) 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
EP1497317B1 (en) 2002-04-09 2006-09-06 Eli Lilly And Company Dipeptidic growth hormone secretagogues
EP1527086B1 (en) * 2002-08-09 2008-01-09 Astellas Pharma Europe B.V. Compounds binding to p-selectin
US20080063599A1 (en) 2002-11-18 2008-03-13 Jorge Setoain Quinquer Compounds Which Can Be Used To Diagnose And Monitor Diseases Associated With The Formation Of Amyloid Protein Fibrils
CA2516685A1 (en) 2003-02-20 2004-09-02 University Of South Florida Peptidomimetic inhibitors of stat3 activity and their medical uses
GB0305704D0 (en) 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
WO2006083424A2 (en) 2004-12-28 2006-08-10 The Trustees Of Columbia University In The City Of New York Radiolabeled compounds and uses thereof
EP1912634A4 (en) 2005-07-29 2010-06-09 Bayer Healthcare Llc PREPARATION AND USE OF BIPHENYL AMINOACIDAL DERIVATIVES TO TREAT OBESITY
US20080029548A1 (en) 2006-05-05 2008-02-07 Ann De Wree Fabric treatment dispensing package
EP3056509A1 (en) 2006-09-08 2016-08-17 Piramal Imaging SA Bombesin analogues for use in diagnosis

Also Published As

Publication number Publication date
BRPI0716554A2 (pt) 2013-09-24
EP2455105A3 (en) 2012-09-05
IL197363A0 (en) 2011-08-01
CO6150196A2 (es) 2010-04-20
EP2063918B1 (en) 2014-02-26
US8557776B2 (en) 2013-10-15
MA30780B1 (fr) 2009-10-01
PE20080850A1 (es) 2008-09-02
WO2008028688A3 (en) 2008-11-13
TW200829277A (en) 2008-07-16
US20080292548A1 (en) 2008-11-27
EP2455105B1 (en) 2016-02-17
JP5722966B2 (ja) 2015-05-27
EP3056509A1 (en) 2016-08-17
IL211527A0 (en) 2011-05-31
CA2858907A1 (en) 2008-03-13
MX2009002492A (es) 2009-08-28
EP2455105A2 (en) 2012-05-23
WO2008028688A2 (en) 2008-03-13
JP5603074B2 (ja) 2014-10-08
EP2279759A3 (en) 2013-04-17
EP2063918A2 (en) 2009-06-03
EP2289564A3 (en) 2012-11-14
IL211033A0 (en) 2011-04-28
EP2279759A2 (en) 2011-02-02
KR20090058553A (ko) 2009-06-09
AU2007294124A1 (en) 2008-03-13
AR062726A1 (es) 2008-11-26
NO20091428L (no) 2009-06-03
RU2009112716A (ru) 2010-10-20
CL2007002620A1 (es) 2008-05-30
TN2009000063A1 (en) 2010-08-19
IL211526A0 (en) 2011-05-31
JP2014028813A (ja) 2014-02-13
EP2289564A2 (en) 2011-03-02
JP2010503618A (ja) 2010-02-04
CA2662449A1 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
CR10654A (es) Agentes que comprenden compuestos marcados con 18f y metodos relacionados
CR11861A (es) Compuestos organicos
UY32611A (es) Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750
CR20120264A (es) Compuestos
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
ECSP14013245A (es) Nuevos derivados dihidroquinolina-2-ona
ECSP10010129A (es) Inhibidores de quinasas símil polo
CR20140275A (es) Triazolopiridinas sustituidas
CR20110135A (es) INHIBIDORES DE cMET
UY31524A1 (es) Nuevos compuestos 010
CU20120084A7 (es) Compuestos derivados de triazolopiridina sustituidos como inhibidores de la quinasa mps-1 y compuestos intermediarios para su preparación
UY32918A (es) Nuevos compuestos de 2-piridona
CR11427A (es) 2-fluoro-2 - desoxitetrahidrouridinas como inhibidores de citidina desaminasa
ECSP11011436A (es) ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS Y MÉTODOS DE USO
UY32077A (es) Inhibidores de quinasa tipo polo
CR9786A (es) Compuestos de bencimidazol-tiofeno
ECSP11011344A (es) Nuevos anticuerpos anti-?5?1 y sus usos
GT201300254A (es) Triazolopiridinas
ECSP12012338A (es) Triazolopiridinas sustituidas
PA8855001A1 (es) Monocarbamas
CR20140135A (es) Nuevos derivados de aril-quinolina
UY29469A1 (es) Compuestos sulfoximino-macrocíclicos y sus sales, composiciones farmacéuticas que comprenden dichos compuestos, métodos de preparación y usos de los mismos.
UY31905A (es) Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
CU24317B1 (es) Conjugado de naloxol-peg cristalino

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)